Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 232-246

  Koliopoulos, George ^a   Arbyn, Marc ^b,c   Martin Hirsch, Pierre ^d   Kyrgiou, Maria ^e   Prendiville, Walter ^f   Paraskevaidis, Evangelos ^g  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^f Pathology Research Laboratory   (Ireland)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cervical cancer; Cytology; Human papillomavirus; Mass screening

Indexed keywords

CANCER CYTODIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; DATA BASE; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; VIRUS ETIOLOGY; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33845982961     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.053     Document Type: Review

References (55)

1. Wilson J.M.G., and Jungner G. Principles and practice of screening for disease. Public Health Papers vol. 34 (1968), World Health Organization, Geneva
2. Quinn M., Babb P., Jones J., and Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318 (1999) 904-908
3. Day N.E. The epidemiological basis for evaluating different screening policies vol. 76 (1986), IARC scientific publications 199-212
4. Sasieni P.D., Cuzick J., and Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 73 (1996) 1001-1005
5. Stoler M.H., and Schiffman M. Atypical squamous cells of undetermined significance-low-grade squamous Intraepithelial Lesion Triage Study (ALTS) group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 285 (2001) 1500-1505
6. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
7. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., and Dillner J. Cytologic versus virologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 96 (2004) 280-293
8. Arbyn M., Dillner J., Buntinx F., Van Ranst M., Martin-Hirsch P., and Paraskevaidis E. Have we resolved how to triage equivocal cervical cytology?. J. Natl. Cancer Inst. 96 (2004) 1401-1402
9. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G., et al. The role of HPV testing in the follow up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev. 30 (2004) 205-211
10. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol. Oncol. 99 Suppl. 3 (2005) 7-11
11. Kurman R.J., and Solomon D. The Bethesda System for reporting cervical/vaginal cytologic diagnoses (1994), Springer-Verlag, New York
12. Cochran W.G. The combination of estimates from different experiments. Biometrics 10 (1954) 101-129
13. Dersimonian R., and Laird N.M. Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986) 177-188
14. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., and Song F. Methods for meta-analysis in medical research (2000), Johns Wiley and Sons Ltd., Chichester, UK 1-317
15. Sharp S., and Sterne J. Meta-analysis. Stata Tech. Bull. 38 (1997) 9-14
16. Paraskevaidis E., Malamou-Mitsi V., Koliopoulos G., Pappa L., Lolis E., Georgiou I., et al. Expanded cytological referral criteria for colposcopy in cervical screening: comparison with human papillomavirus testing. Gynecol. Oncol. 82 (2001) 355-359
17. Blumenthal P.D., Gaffikin L., Chirenje Z.M., McGrath J., Womack S., and Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int. J. Gynaecol. Obstet. 72 (2001) 47-53
18. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer 84 (2001) 1616-1623
19. Costa S., Sideri M., Syrjanen K., Terzano P., De Nuzzo M., De Simone P., et al. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. Acta Cytol. 44 (2000) 310-318
20. Coste J., Cochand-Priollet B., de Cremoux P., Le Gales C., Cartier I., Molinie V., et al., French Society of Clinical Cytology Study Group. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ 326 (2003) 733
21. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P., et al. Human papillomavirus testing in primary cervical screening. Lancet 345 (1995) 1533-1536
22. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., et al. HPV testing in primary screening of older women. Br. J. Cancer 81 (1999) 554-558
23. Kuhn L., Denny L., Pollack A., Lorincz A., Richart R.M., and Wright T.C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J. Natl. Cancer Inst. 92 (2000) 818-825
24. Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
25. Oh Y.L., Shin K.J., Han J., and Kim D.S. Significance of high-risk human papillomavirus detection by polymerase chain reaction in primary cervical cancer screening. Cytopathology 12 (2001) 75-83
26. Pan Q., Belinson J.L., Li L., Pretorius R.G., Qiao Y.L., Zhang W.H., et al. A thin-layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma. A cross-sectional, comparative study. Acta Cytol. 47 (2003) 45-50
27. Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer 88 (2003) 1570-1577
28. Salmeron J., Lazcano-Ponce E., Lorincz A., Hernandez M., Hernandez P., Leyva A., et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14 (2003) 505-512
29. Schiffman M., Herrero R., Hildesheim A., Sherman M.E., Bratti M., Wacholder S., et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283 (2000) 87-93
30. Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int. J. Cancer 89 (2000) 529-534
31. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 95 (2003) 46-52
32. Syrjaenen S., and Shabalova I. Human papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former Soviet Union. J. Low. Genit. Tract Dis. 6 (2002) 97-110
33. Cuzick J., Swarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. The Lancet 362 (2003) 1871-1876
34. Sankaranarayanan R., Chatterji R., Shastri S.S., Wesley R.S., Basu P., Mahe C., et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int. J. Cancer 112 (2004) 341-347
35. Sankaranarayanan R., Thara S., Sharma A., Roy C., Shastri S., Mahe C., et al. Accuracy of conventional cytology: results from a multicentre screening study in India. J. Med. Screen. 11 (2004) 77-84
36. Agorastos T., Dinas K., Lloveras B., de Sanjose S., Kornegay J.R., Bonti H., et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecol. Oncol. 96 (2005) 714-720
37. Sarian L.O., Derchain S.F., Naud P., Roteli-Martins C., Longatto-Filho A., Tatti S., et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's Iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS study. J. Med. Screen. 12 (2005) 142-149
38. Sankaranarayanan R., Nene B.M., Dinshaw K.A., Mahe C., Jayant K., Shastri S., et al. A cluster randomized controlled trial of visual, cytological and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer 116 (2005) 617-623
39. Bigras G., and de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br. J. Cancer 93 (2005) 575-581
40. Ratnam S., Franco E.L., and Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol., Biomarkers Prev. 9 (2000) 945-951
41. Belinson J.L., Qiao Y.L., Pretorius R.G., Zhang W.H., Rong S.D., Huang M.N., et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int. J. Gynecol. Cancer 13 (2003) 819-826
42. Womack S.D., Chirenje Z.M., Blumenthal P.D., Gaffikin L., McGrath J.A., Chipato T., et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG 107 (2000) 33-38
43. Denny L., Kuhn L., Pollack A., Wainwright H., and Wright Jr. T.C. Evaluation of alternative methods of cervical cancer screening for resource poor settings. Cancer 89 (2000) 826-833
44. Shastri S.S., Dinshaw K., Amin G., Goswami S., Patil S., Chinoy R., et al. Concurrent evaluation of visual, cytological, and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull. World Health Organ. 83 (2005) 186-194
45. Belinson J., Qiao Y.L., Pretorius R., Zhang W.H., Elson P., Li L., et al. Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol. Oncol. 83 (2001) 439-444
46. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 (2002) 2372-2381
47. Meera E., Le Gales C., Cochand-Priollet B., Cartier I., de Cremoux P., Vacher-Lavenu M.C., et al. Cost of screening for cancerous and precancerous lesions of the cervix. Diagn. Cytopathol. 27 (2002) 251-257
48. McCaffery K., Waller J., Forrest S., Cadman L., Szarewski A., and Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 111 (2004) 1437-1443
49. Kjaer S. Long term predictive value of HPV testing (the Danish prospective cohort study) [Abstract 339]. 21st International papillomavirus Conference, Mexico City, Feb 20-26, 2004.
50. Ferreccio C., Bratti M.C., Sherman M.E., Herrero R., Wacholder S., Hildesheim A., et al. A comparison of single and combined visual, cytologic and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol., Biomarkers Prev. 12 (2003) 815-823
51. Wright T.C., Schiffman M.A., Solomon D., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103 (2004) 304-309
52. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119 (2006) 1095-1101
53. Davies P., Arbyn M., Dillner J., Kitchener H.C., Meijer C.J., Ronco G., et al. A report on the current status of European research on the use of Human Papillomavirus testing for primary cervical cancer screening. Int. J. Cancer 118 (2006) 791-796
54. Schatzkin A., Connor R.J., Taylor P.R., and Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. Am. J. Epidemiol. 125 (1987) 672-678
55. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24 S3 (2006) 78-89